Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC.

Pi-Hung TungTzu-Hsuan ChiuAllen Chung-Cheng HuangJia-Shiuan JuChi-Hsien HuangChin-Chou WangHow-Wen KoFu-Tsai ChungPing-Chih HsuYueh-Fu FangYi-Ke GuoChih-Hsi Scott KuoCheng-Ta Yang

Published in: Therapeutic advances in medical oncology (2024)

T790M positivity predicts better post-progression OS than T790M negativity; tumor T790M positivity has a stronger prognostic impact than plasma T790M positivity. Osimertinib and chemotherapy provide similar OS benefits in patients with T790M-positive tumors.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
squamous cell carcinoma
brain metastases
locally advanced
radiation therapy
chronic myeloid leukemia
newly diagnosed